Evidence map›Paper›PMID 27158095›Full record

ReviewAdvanced drug delivery reviews2016

Microbiome therapeutics - Advances and challenges.

Mark Mimee, Robert J Citorik, Timothy K Lu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Special Issue "Alcohol and Inflammation".International journal of molecular sciences · 2026
    Article
  10. Review
  11. Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  18. Article
  19. Review
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mark MimeeMIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA, USA; MIT Synthetic Biology Center, 500 Technology Square, Cambridge, MA, USA; The Center for Microbiome Informatics and Therapeutics, Cambridge, MA, USA.
Robert J CitorikMIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA, USA; MIT Synthetic Biology Center, 500 Technology Square, Cambridge, MA, USA; The Center for Microbiome Informatics and Therapeutics, Cambridge, MA, USA.
Timothy K LuMIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA, USA; MIT Synthetic Biology Center, 500 Technology Square, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA; The Center for Microbiome Informatics and Therapeutics, Cambridge, MA, USA. Electronic address: timlu@mit.edu.

Funding

Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
MIT Center for Integrative Synthetic BiologyP50GM098792 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEISS, RON · 2013 to 2017
$11.0M
Mucin Glycans in the Regulation of Microbial VirulenceR01EB017755 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI RIBBECK, KATHARINA · 2013 to 2022
$3.6M
High-Throughput Nanoscale Approaches to Studying and Inhibiting Amyloid ToxicityDP2OD008435 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LU, TIMOTHY · 2011 to 2011
$2.4M
Howard Hughes Medical InstituteNIBIB NIH HHS R01 EB017755NIDDK NIH HHS P30 DK043351NIGMS NIH HHS P50 GM098792NIH HHS DP2 OD008435
6 · The paper itself

Abstract

The microbial community that lives on and in the human body exerts a major impact on human health, from metabolism to immunity. In order to leverage the close associations between microbes and their host, development of therapeutics targeting the microbiota has surged in recent years. Here, we discuss current additive and subtractive strategies to manipulate the microbiota, focusing on bacteria engineered to produce therapeutic payloads, consortia of natural organisms and selective antimicrobials. Further, we present challenges faced by the community in the development of microbiome therapeutics, including designing microbial therapies that are adapted for specific geographies in the body, stable colonization with microbial therapies, discovery of clinically relevant biosensors, robustness of engineered synthetic gene circuits and addressing safety and biocontainment concerns. Moving forward, collaboration between basic and applied researchers and clinicians to address these challenges will poise the field to herald an age of next-generation, cellular therapies that draw on novel findings in basic research to inform directed augmentation of the human microbiota.

Indexed as

MicrobiotaAnimalsAnti-Infective AgentsBioengineeringHumansProbioticsAnti-Infective AgentsBacteriophageHost-bacteria interactionsMicrobial ecologyMicrobiomeSynthetic biology

Identifiers

PMID27158095
PMCPMC5093770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.